Literature DB >> 21197620

TRAIL shows potential cardioprotective activity.

Barbara Toffoli1, Stella Bernardi, Riccardo Candido, Serena Zacchigna, Bruno Fabris, Paola Secchiero.   

Abstract

Recent clinical trials carried out in patients with advanced cancer have shown that recombinant TRAIL administration is usually safe and well tolerated when used either alone or in association with chemotherapeutic drugs. Notably, anticancer chemotherapy can be associated to cardiomiopathy. We have here demonstrated that TRAIL (administrated as either recombinant soluble TRAIL or as AAV-TRAIL expression viral vector) reduced the development of cardiomyopathy in the ApoE(-/-) diabetic mouse model. These data suggest, for the first time, that therapeutically administration of TRAIL might have a cardioprotective effect.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21197620     DOI： 10.1007/s10637-010-9627-8

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  14 in total

1.  TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells.

Authors:  P Secchiero; C Zerbinati; E Rimondi; F Corallini; D Milani; V Grill; G Forti; S Capitani; G Zauli
Journal:  Cell Mol Life Sci       Date:  2004-08       Impact factor: 9.261

2.  A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes.

Authors:  Riccardo Candido; Josephine M Forbes; Merlin C Thomas; Vicki Thallas; Rachael G Dean; Wendy C Burns; Christos Tikellis; Rebecca H Ritchie; Stephen M Twigg; Mark E Cooper; Louise M Burrell
Journal:  Circ Res       Date:  2003-03-06       Impact factor: 17.367

3.  Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.

Authors:  Steven E Lipshultz; Rebecca E Scully; Stuart R Lipsitz; Stephen E Sallan; Lewis B Silverman; Tracie L Miller; Elly V Barry; Barbara L Asselin; Uma Athale; Luis A Clavell; Eric Larsen; Albert Moghrabi; Yvan Samson; Bruno Michon; Marshall A Schorin; Harvey J Cohen; Donna S Neuberg; E John Orav; Steven D Colan
Journal:  Lancet Oncol       Date:  2010-09-16       Impact factor: 41.316

4.  Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer.

Authors:  Jean-Charles Soria; Egbert Smit; David Khayat; Benjamin Besse; Xinqun Yang; Cheng-Pang Hsu; David Reese; Jeffrey Wiezorek; Fiona Blackhall
Journal:  J Clin Oncol       Date:  2010-02-16       Impact factor: 44.544

Review 5.  Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L.

Authors:  Roberta Di Pietro; Giorgio Zauli
Journal:  J Cell Physiol       Date:  2004-12       Impact factor: 6.384

6.  Dose and time-dependent apoptotic effects by angiotensin II infusion on left ventricular cardiomyocytes.

Authors:  Bruno Fabris; Riccardo Candido; Monica Bortoletto; Lorena Zentilin; Marco Sandri; Francesco Fior; Barbara Toffoli; Marco Stebel; Moreno Bardelli; Dario Belgrado; Mauro Giacca; Renzo Carretta
Journal:  J Hypertens       Date:  2007-07       Impact factor: 4.844

Review 7.  Tumor-necrosis-factor-related apoptosis-inducing ligand and the regulation of hematopoiesis.

Authors:  Paola Secchiero; Giorgio Zauli
Journal:  Curr Opin Hematol       Date:  2008-01       Impact factor: 3.284

8.  Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells.

Authors:  Daniela Milani; Giorgio Zauli; Erika Rimondi; Claudio Celeghini; Sandra Marmiroli; Paola Narducci; Silvano Capitani; Paola Secchiero
Journal:  J Neurochem       Date:  2003-07       Impact factor: 5.372

9.  Association of serum TRAIL level with coronary artery disease.

Authors:  Katsuhito Mori; Yuji Ikari; Shuichi Jono; Atsushi Shioi; Eiji Ishimura; Masanori Emoto; Masaaki Inaba; Kazuhiro Hara; Yoshiki Nishizawa
Journal:  Thromb Res       Date:  2010-01-19       Impact factor: 3.944

10.  Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction.

Authors:  Paola Secchiero; Federica Corallini; Claudio Ceconi; Giovanni Parrinello; Stefano Volpato; Roberto Ferrari; Giorgio Zauli
Journal:  PLoS One       Date:  2009-02-16       Impact factor: 3.240
View more
  17 in total

1.  Soluble TNF-related apoptosis induced ligand (sTRAIL) is augmented by Post-Conditioning and correlates to infarct size and left ventricle dysfunction in STEMI patients: a substudy from a randomized clinical trial.

Authors:  André Luz; Mário Santos; Rui Magalhães; José Carlos Oliveira; Ana Pacheco; João Silveira; Sofia Cabral; Severo Torres; Adelino F Leite-Moreira; Henrique Carvalho
Journal:  Heart Vessels       Date:  2016-05-26       Impact factor: 2.037

2.  Angiogenic microenvironment augments impaired endothelial responses under diabetic conditions.

Authors:  Abdul Q Sheikh; Courtney Kuesel; Toloo Taghian; Jennifer R Hurley; Wei Huang; Yigang Wang; Robert B Hinton; Daria A Narmoneva
Journal:  Am J Physiol Cell Physiol       Date:  2014-02-26       Impact factor: 4.249

Review 3.  Cell-based therapies for diabetic complications.

Authors:  Stella Bernardi; Giovanni Maria Severini; Giorgio Zauli; Paola Secchiero
Journal:  Exp Diabetes Res       Date:  2011-06-09

Review 4.  Treatment, behavioral, and psychosocial components of cardiovascular disease risk among survivors of childhood and young adult cancer.

Authors:  Amy M Berkman; Susan G Lakoski
Journal:  J Am Heart Assoc       Date:  2015-04-02       Impact factor: 5.501

Review 5.  TRAIL modulates the immune system and protects against the development of diabetes.

Authors:  Fleur Bossi; Stella Bernardi; Giorgio Zauli; Paola Secchiero; Bruno Fabris
Journal:  J Immunol Res       Date:  2015-02-18       Impact factor: 4.818

6.  Dyslipidemia and Diabetes Increase the OPG/TRAIL Ratio in the Cardiovascular System.

Authors:  Barbara Toffoli; Bruno Fabris; Giacomo Bartelloni; Fleur Bossi; Stella Bernardi
Journal:  Mediators Inflamm       Date:  2016-12-14       Impact factor: 4.711

Review 7.  Apoptosis in ischemic heart disease.

Authors:  Elena Teringova; Petr Tousek
Journal:  J Transl Med       Date:  2017-05-01       Impact factor: 5.531

8.  Prognostic value of TNF-related apoptosis inducing ligand (TRAIL) in acute coronary syndrome patients.

Authors:  Pavel Osmancik; Elena Teringova; Petr Tousek; Petra Paulu; Petr Widimsky
Journal:  PLoS One       Date:  2013-02-18       Impact factor: 3.240

Review 9.  Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular Disease.

Authors:  Stella Bernardi; Fleur Bossi; Barbara Toffoli; Bruno Fabris
Journal:  Biomed Res Int       Date:  2016-04-21       Impact factor: 3.411

Review 10.  Addressing Stem Cell Therapeutic Approaches in Pathobiology of Diabetes and Its Complications.

Authors:  Bou-Yue Peng; Navneet Kumar Dubey; Viraj Krishna Mishra; Feng-Chou Tsai; Rajni Dubey; Win-Ping Deng; Hong-Jian Wei
Journal:  J Diabetes Res       Date:  2018-06-25       Impact factor: 4.011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.